TGFB1 and neoplasm: The mainstream of such developing therapies nowadays are immunotherapies, including cancer vaccines employing mRNA encoding for tumor associated antigens 51-54, mRNA expressing monoclonal antibodies against such antigens 55, and immunomodulating cytokines such as IL-12 and TGF-β- encoding mRNA 56-59.